

The board of directors' of Active Biotech AB (publ) proposal to resolve on a new share issue with pre-emptive rights for the shareholders

The board of directors proposes that the general meeting resolves to increase the company's share capital through issue of new shares. The following terms shall apply.

1. The record date for the right to participate in the rights issue shall be 4 January 2021.
2. The shareholders of the company shall be entitled to subscribe for the new shares with pre-emptive rights.
3. Shares not subscribed for with pre-emptive rights shall be allocated to persons that have subscribed for shares by exercise of subscription rights and have subscribed for shares also without pre-emptive rights, whereby – in the event of over-subscription – allocation shall be made in relation to the number of subscription rights such persons have exercised for subscription and, to the extent such allocation cannot be effected, by the drawing of lots. Thereafter, allocation shall be made to other persons that have subscribed for shares without pre-emptive rights, whereby – in the event of over-subscription – allocation shall be made in relation to the number of shares set forth in the respective subscription form and, to the extent such allocation cannot be effected, by the drawing of lots. Any thereafter remaining shares shall be allocated to such persons who have undertaken to subscribe for shares in the rights issue pursuant to agreements with the company, whereby allocation shall be made in relation to the undertakings made.
4. The new shares shall entitle to dividends for the first time on the record date for dividends that occurs immediately following the registration of the new shares in the company's share register.
5. Subscription shall be made during the period 7 January – 21 January 2021 or, as regards subscription pursuant to the last sentence of section 3, no later than three business days thereafter. However, the board of directors shall be entitled to extend the subscription period.
6. Subscription with pre-emptive rights shall be made by cash payment.
7. Subscription without pre-emptive rights shall be made on a specific subscription form within the time period set forth in section 5, following which payment shall be made in cash in accordance with instructions on the contract note, however no later than three business days following receipt of the contract note.
8. The board of directors shall, not later than on 25 November 2020, present its proposal on (i) the highest amount that the company's share capital may be increased by, (ii) the highest number of shares that may be issued and (iii) the subscription price for each new share.
9. The board of director's resolution on the terms of the rights issue under section 8 above must not result in the company's share capital and number of shares, following the rights issue, exceed the highest share capital and number of shares allowed under the company's articles of association.
10. The company's CEO and President is authorised to make such minor adjustments to this resolution that may be necessary in connection with the registration thereof.

Documents pursuant to Chapter 13 Section 6 of the Swedish Companies Act have been prepared.